Aadi Sub Drug Patent Portfolio
Aadi Sub owns 1 orange book drug protected by 7 US patents Given below is the list of Aadi Sub's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497737 | Pharmaceutical compositions of albumin and rapamycin | 28 Oct, 2040 | Active |
| US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin | 29 Jun, 2036 | Active |
| US12133844 | Methods of treating epithelioid cell tumors | 29 Jun, 2036 | Active |
| US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | 05 Mar, 2036 | Active |
| US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | 05 Mar, 2036 | Active |
| US10206887 | Prion free nanoparticle compositions and methods of making thereof | 15 Apr, 2030 | Active |
| US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent | 14 Feb, 2029 | Active |
Latest Legal Activities on Aadi Sub's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aadi Sub.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 08 Jul, 2025 | US8911786 |
| FDA Final Eligibility Letter | 21 May, 2025 | US8911786 |
| Mail Patent eCofC Notification | 25 Feb, 2025 | US12061183 |
| Mail Patent eCofC Notification | 25 Feb, 2025 | US12133844 |
| Patent eCofC Notification | 25 Feb, 2025 | US12133844 |
| Recordation of Patent eCertificate of Correction | 25 Feb, 2025 | US12133844 |
| Patent eCofC Notification | 25 Feb, 2025 | US12061183 |
| Recordation of Patent eCertificate of Correction | 25 Feb, 2025 | US12061183 |
| Email Notification | 25 Feb, 2025 | US12133844 |
| Email Notification | 25 Feb, 2025 | US12061183 |
| Post Issue Communication - Certificate of Correction | 06 Feb, 2025 | US12061183 |
| Mail Certificate of Correction Memo | 31 Jan, 2025 | US12061183 |
| Certificate of Correction Memo | 29 Jan, 2025 | US12061183 |
| Email Notification | 05 Nov, 2024 | US12133844 |
| Patent eGrant Notification | 05 Nov, 2024 | US12133844 |
Aadi Sub's Family Patents
Aadi Sub drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 22.2% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Aadi Sub Drug List
Given below is the complete list of Aadi Sub's drugs and the patents protecting them.
1. Fyarro
Fyarro is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497737 | Pharmaceutical compositions of albumin and rapamycin |
28 Oct, 2040
(14 years from now)
| Active |
| US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
29 Jun, 2036
(10 years from now)
| Active |
| US12133844 | Methods of treating epithelioid cell tumors |
29 Jun, 2036
(10 years from now)
| Active |
| US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
05 Mar, 2036
(9 years from now)
| Active |
| US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
05 Mar, 2036
(9 years from now)
| Active |
| US10206887 | Prion free nanoparticle compositions and methods of making thereof |
15 Apr, 2030
(4 years from now)
| Active |
| US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent |
14 Feb, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fyarro's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List